Table 1. Patient characteristics, toxicity, and response.
Lymphodepletion
CategoryCy or Cy/ECy/FluTotal
PatientsEvaluablen = 12n = 20n = 32
Age (years)Median (range)60 (52–68)53 (36–70)58 (36–70)
SexMale11 (92%)16 (80%)27/32 (84%)
Female1 (8%)4 (20%)5/32 (16%)
Prior regimens≤24 (36%)3 (15%)7/32 (22%)
3-42 (18%)5 (25%)7/32 (22%)
≥56 (50%)12 (60%)18/32 (56%)
Prior autologous HCTYes6 (50%)8 (40%)14/32 (44%)
No6 (50%)12 (60%)18/32 (56%)
Prior allogeneic HCTYes1 (8%)3 (15%)4/32 (13%)
No11 (92%)17 (85%)28/32 (88%)
HistologyDe novo aggressive B cell lymphoma4 (33%)7 (35%)11/32 (34%)
Transformed LBCL4 (33%)7 (35%)11/32 (34%)
Follicular lymphoma2 (17%)4 (20%)6/32 (19%)
Mantle cell lymphoma2 (17%)2 (10%)4/32 (13%)
ChemorefractoryYes11 (92%)18 (90%)29/32 (91%)
No/indeterminate1 (8%)2 (10%)3/32 (9%)
ToxicityEvaluablen = 12n = 20n = 32
sCRS2 × 105 EGFRt+ cells/kg0/2 (0%)0/3 (0%)0/5 (0%)
2 × 106 EGFRt+ cells/kg0/7 (0%)1/11 (9%)1/18 (6%)
2 × 107 EGFRt+ cells/kg0/3 (0%)3/6 (50%)3/9 (33%)
Total0 (0%)4/20 (20%)4/32 (13%)
Grade ≥3 neurotoxicity2 × 105 EGFRt+ cells/kg0/2 (0%)1/3 (33%)1/5 (20%)
2 × 106 EGFRt+ cells/kg2/7 (29%)2/11 (18%)4/18 (22%)
2 × 107 EGFRt+ cells/kg0/3 (0%)4/6 (67%)4/9 (44%)
Total2/12 (17%)7/20 (35%)9/32 (28%)
ResponseEvaluablen = 12n = 18n = 30
CRDe novo aggressive B cell lymphoma0/4 (0%)2/7 (29%)2/11 (18%)
Transformed LBCL1/4 (25%)5/6 (83%)6/10 (60%)
Follicular lymphoma0/2 (0%)2/3 (67%)2/5 (40%)
Mantle cell lymphoma0/2 (0%)0/2 (0%)0/4 (0%)
2 × 105 EGFRt+ cells/kg0/2 (0%)1/3 (33%)1/5 (20%)
2 × 106 EGFRt+ cells/kg1/7 (14%)7/11 (64%)8/18 (44%)
2 × 107 EGFRt+ cells/kg0/3 (0%)1/4 (25%)1/7 (14%)
Total1/12 (8%)9/18 (50%)10/30 (33%)
ORRDe novo aggressive B cell lymphoma1/4 (25%)6/7 (86%)7/11 (64%)
Transformed LBCL2/4 (50%)5/6 (83%)7/10 (70%)
Follicular lymphoma2/2 (100%)2/3 (67%)4/5 (80%)
Mantle cell lymphoma1/2 (50%)0/2 (0%)1/4 (25%)
2 × 105 EGFRt+ cells/kg2/2 (100%)1/3 (33%)3/5 (60%)
2 × 106 EGFRt+ cells/kg3/7 (43%)9/11 (82%)12/18 (67%)
2 × 107 EGFRt+ cells/kg1/3 (33%)3/4 (75%)4/7 (57%)
Total6/12 (50%)13/18 (72%)19/30 (63%)